

Sustain

Through our ongoing commitment to disciplined science and strategic focus, we will carry our success into the future.

Increasing the competitiveness of our anti-infective franchise.

2002 was a year of tremendous achievement for Gilead, evidenced by important new product launches, profitability and the strategic acquisition of Triangle Pharmaceuticals. To sustain growth and maintain our reputation as one of the industry's most efficient and productive research, development and commercialization enterprises, we will continue to draw upon the strength of our scientific expertise while being opportunistic in our corporate development initiatives.

Translating proprietary research into clinical candidates.

In 2002, we advanced our early-stage pipeline through internal research and development efforts. We initiated a Phase I/II study of GS 7340, a new oral prodrug of tenofovir, the active agent in Viread® (tenofovir disoproxil fumarate). This proof-of-concept study is designed to determine if this novel prodrug technology could result in a compound with an even greater level of potency than Viread, while retaining Viread's beneficial side effect and convenience profile. In addition, we recently announced the discovery of GS 74338, a novel HIV protease inhibitor designed to be potent, to possess a unique resistance profile compared with currently marketed drugs in its class and to have the potential for once-daily dosing.

Augmenting our pipeline through strategic acquisitions.

In late January 2003, Gilead completed the acquisition of Triangle Pharmaceuticals. The Triangle product portfolio brings to Gilead a unique opportunity to drive the future growth of our existing products and to strengthen our therapeutic focus on HIV and hepatitis B.

The acquisition enriches Gilead's pipeline with the late-stage antiviral emtricitabine (FTC), a one-pill, once-daily nucleoside analogue for the potential treatment of HIV, now under review for marketing approval by regulatory authorities in the United States and Europe. Beyond pursuing the commercialization of this antiviral as a single agent, Gilead has initiated development of a co-formulation of Viread and emtricitabine as a potential fixed-dose treatment for patients with HIV, that could result in the first combination drug dosed as one pill, once daily.

ability



Sustainability

As exemplified by the successful U.S. launches of Viread and Hepsera™ (adefovir dipivoxil) within the span of one year, Gilead is well positioned to effectively launch emtricitabine for the treatment of HIV, immediately following marketing clearance.

Emtricitabine also is being evaluated in a Phase III study for patients with chronic hepatitis B. In addition, the Triangle acquisition augments Gilead's pipeline with amdoxovir (DAPD), a nucleoside analogue in Phase II clinical studies for the treatment of HIV, and clevudine (L-FMAU), a nucleoside analogue in Phase I/II studies for the treatment of chronic hepatitis B.

Focusing on what we do best.

We have endeavored to build a portfolio of innovative therapeutics for the treatment of life-threatening infectious diseases. United by the shared values of integrity, teamwork, accountability and excellence, in 2002 we utilized our integrated discovery, development and commercialization abilities to their fullest. The results included significant industry achievements and the fulfillment of our promise to advance care.

“Our ability to provide rapid access to important new treatment options and continue to grow as an organization hinges upon our capacity to develop and sustain the relationships that we have built with regulatory agencies, physicians and patients worldwide.”

In striving to meet these goals, in February 2003 Gilead's achievements were recognized with the James D. Watson Helix Award, presented annually to biotechnology companies that have demonstrated corporate excellence. Conferred by the Biotechnology Industry Organization and the Long Island Life Sciences Initiative, the award honors organizations that have demonstrated outstanding leadership, significant scientific and product advancements, economic development and solid corporate citizenry. We are very honored to have received this award in recognition of our commitments and achievements.

Looking to the future, we will sustain our success by remaining steadfast in our resolve to make a difference – in our science, in our business and in the lives of people around the world.



Corporate Directory and Information

Board of Directors

James M. Denny
Chairman,
Gilead Sciences Board of Directors

Paul Berg, PhD
Nobel Prize Winner, Chemistry
Cahill Professor, Stanford University

Etienne F. Davignon
Vice Chairman,
Société Générale de Belgique

Cordell W. Hull
Co-founder, Chairman and
Chief Executive Officer,
InfrastructureWorld, Inc.

John C. Martin, PhD
President and Chief Executive Officer,
Gilead Sciences

Gordon E. Moore, PhD
Chairman Emeritus, Intel Corporation

George P. Shultz, PhD
Distinguished Fellow, Hoover Institution,
Stanford University

Gayle E. Wilson
Director, Chela Financial, Inc. and
Ralph M. Parsons Foundation

Executive Committee

John C. Martin, PhD
President and Chief Executive Officer

Norbert W. Bischofberger, PhD
Executive Vice President,
Research and Development

Mark L. Perry, JD
Executive Vice President, Operations

Michael K. Inouye
Senior Vice President,
Commercial Operations

William A. Lee, PhD
Senior Vice President,
Research

John F. Milligan, PhD
Senior Vice President and
Chief Financial Officer

Anthony D. Caracciolo
Vice President, Manufacturing Operations

Marsha Roberts
Vice President, Human Resources

Management Team

Michael W. Aguiar
Vice President, Finance

Gregg H. Alton
Vice President and General Counsel

Mark Bosse, PhD, JD
Vice President, Intellectual Property

Carol L. Brosgart, MD
Vice President, Clinical Research

Arnold Fridland, PhD
Vice President, Drug Metabolism

Christopher Garabedian
Vice President, Global Marketing

Mercedes Garcia
Vice President, European Operations

Michael J. M. Hitchcock, PhD
Vice President and Chief of Staff,
Research and Development

Choung U. Kim, PhD
Vice President, Chemistry

James R. Meyers
Vice President, U.S. Sales

Ernest J. Prisbe
Vice President, Chemical Development

James F. Rooney, MD
Vice President, Clinical Research

Alan S. Taylor, PhD
Vice President, Regulatory Affairs

Jay Toole, MD, PhD
Vice President, Clinical Research

Shay H. Weisbrich
Vice President,
Sales and Marketing

Michael Wulfsohn, MD, PhD
Vice President, Biometrics

Taiyin Yang, PhD
Vice President, Pharmaceutical
Development and Manufacturing

Scientific Advisory Board

Bernard M. Wagner, MD (Chairman)
New York University Medical Center

Jacqueline K. Barton, PhD
California Institute of Technology

Paul Berg, PhD
Stanford University School of Medicine

Peter B. Dervan, PhD
California Institute of Technology

Ralph F. Hirschmann, PhD
University of Pennsylvania

Howard S. Jaffe, MD
University of California, San Francisco

Paul E. Klotman, MD
Mount Sinai Medical Center

John W. Mellors, MD
University of Pittsburgh School
of Medicine

Eugene R. Schiff, MD
University of Miami School of Medicine

Robert (Chip) Schooley, MD
University of Colorado Health Sciences Center

Richard J. Whitley, MD
University of Alabama at Birmingham

Equal Opportunity Employer

Gilead Sciences is an equal opportunity employer. Working together, we benefit from the unique ideas and skills that each individual contributes. We value different perspectives, styles and approaches to our work, viewing our differences as a catalyst for innovation that enables us to reach higher levels of excellence. For these reasons, we strive to enrich the diversity of our workforce in the way we recruit, retain and develop our people.